The state of West Virginia currently has 5 active clinical trials seeking participants for Alzheimer's Disease research studies. These trials are conducted in various cities, including Morgantown, Charleston, Huntington and Wheeling.
A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)
Recruiting
The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).
Gender:
All
Ages:
Between 65 years and 80 years
Trial Updated:
04/18/2024
Locations: Option Care - Charleston WV, Charleston, West Virginia +1 locations
Conditions: Alzheimer Disease
Phase 3, Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants With Early Alzheimer's Disease (Polaris-AD)
Recruiting
This AR1001-ADP3-US01 protocol is a double-blind, randomized, placebo-controlled, multi- center, parallel-group comparison pivotal Phase 3 study to evaluate the efficacy and safety of AR1001 for the treatment of participants with early AD.
Gender:
All
Ages:
Between 55 years and 90 years
Trial Updated:
03/20/2024
Locations: Vaught Neurological Services, PLLC, Crab Orchard, West Virginia
Conditions: Alzheimer Disease
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
Recruiting
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
03/04/2024
Locations: West Virginia University Rockefeller Neuroscience Center, Morgantown, West Virginia
Conditions: Alzheimer Disease
Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer's Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
Recruiting
The purpose of this study is to assess the safety and feasibility of administering standard of care monoclonal antibody (mAb) infusion therapy in combination with opening the blood-brain barrier with the Exablate Model 4000 Type 2 device in patients with mild Alzheimer's disease (AD) or mild cognitive impairment (MCI).
Gender:
All
Ages:
Between 50 years and 85 years
Trial Updated:
02/16/2024
Locations: West Virginia University Rockefeller Neuroscience Institute, Morgantown, West Virginia
Conditions: Mild Cognitive Impairment, Alzheimer Disease 1
Low-Intensity Focused Ultrasound (LIFU) Neuromodulation
Recruiting
This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with mild cognitive impairment ( MCI) due to Alzheimer's disease.
Gender:
All
Ages:
Between 45 years and 85 years
Trial Updated:
12/19/2023
Locations: Rockefeller Neuroscience Institute at West Virginia University, Morgantown, West Virginia
Conditions: Alzheimer Disease